Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 342 participants.

Also called NCT01291641

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 342 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01291641
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01291641. Randomized; single masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2016-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease
Acronym
IMPACTonIMT
Condition
Hyperlipidemias
Intervention (Drug)
HMG-CoA Reductase Inhibitor
Intervention (Drug)
Probucol
Intervention (Drug)
Cilostazol
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Korea Otsuka Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01291641
Content hash
9052730b8927cfda4d57b80f1eb454643d2ed61f3e7046a34b2987d08055a55e